RxDoctor Payments Data

Karen Hill

Family · Chatham, VANPI 1518935634

Payments from drug & device makers

$273in general payments, 2019–2025

Across 15 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$54
  • Ardelyx, Inc.$37
  • AstraZeneca$34
  • Hologic Sales And Service, LLC$24
  • AbbVie$23
  • Gilead$22
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$54
Ardelyx, Inc.2$37
AstraZeneca2$34
Hologic Sales And Service, LLC1$24
AbbVie1$23
Gilead1$22
Lilly USA, LLC1$18
Exact Sciences1$17
Amgen1$16
Bayer1$15
Dysis Medical, Inc.1$13

How this compares

$273 in reported general payments places this provider in the 45th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$1,236
Medicare patients
61
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin178$147,543
OzempicSemaglutide120$131,541
TrulicityDulaglutide87$95,219
JanuviaSitagliptin Phosphate87$91,483
Tresiba Flextouch U-200Insulin Degludec69$41,866
FarxigaDapagliflozin Propanediol42$39,597
JardianceEmpagliflozin37$35,408
RybelsusSemaglutide19$33,839
XareltoRivaroxaban52$33,034
Janumet XrSitagliptin Phos/Metformin Hcl44$26,834
LinzessLinaclotide44$26,144
EliquisApixaban40$23,183
VascepaIcosapent Ethyl63$17,788
Tresiba Flextouch U-100Insulin Degludec42$16,453
Victoza 2-PakLiraglutide22$11,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$165,381139 claims
Lilly USA, LLCTrulicity$18$95,21987 claims
AstraZenecaFarxiga, Symbicort$34$42,35055 claims
AbbVieLinzess$23$26,14444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,332 family providers in Virginia.

Other family in Chatham

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →